Shire expands broad monoclonal antibody research platform
Shire obtains worldwide license to pursue development and commercialization of a novel, potentially differentiated, pre-clinical bi-specific antibody candidate for Hemophilia A.
Shire has entered into an agreement granting Shire exclusive worldwide rights to develop and commercialize an innovative, bi-specific antibody in pre-clinical development for the treatment of hemophilia A and hemophilia A patients with inhibitors. Shire is leading the development of the program to optimize and evaluate a fully-human, bi-specific IgG antibody targeting FIXa and FX, designed to imitate the body’s natural mechanism of Factor VIII-driven coagulation. The company’s ultimate aim is to deliver a treatment that improves upon the strong and long-term record of efficacy and safety that has been set by the Factor class.
“This novel program builds on our extensive monoclonal antibody (MAb) capabilities, as well as on our in-depth scientific expertise in hematology,” said Fritz Scheiflinger, Head Global Research, Shire. “While further development and clinical trials are needed to fully evaluate this antibody, we are encouraged by the potential of the data that we have seen in early discovery and the promise it may hold for hemophilia A patients and patients with inhibitors.”
Shire has been steadily building its MAb research capability, which now includes MAb programs in hereditary angioedema (HAE), diabetic macular edema, antibody-mediated autoimmune disease, and anti-thrombotic therapy—all signatures of Shire’s new Rare Diseases Innovation Center coming to Cambridge, MA.
“Novimmune is building on a collaboration initiated in 2015 with Shire to generate and evaluate Factor VIII-mimetic, bi-specific antibodies,” said Ed Holdener, Chairman and CEO of Novimmune. “We are delighted that our research efforts have produced several promising and potentially highly differentiated leads for improving coagulation in hemophilia A.”
Novimmune has been developing a platform for making fully human, bi-specific antibodies and has several in-house programs targeting tumor associated antigens and the immune system check point protein CD47.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance